Search

Your search keyword '"Bronstein, Yotam"' showing total 28 results
Start Over Author "Bronstein, Yotam"
28 results on '"Bronstein, Yotam"'

2. Efficacy of front-line ibrutinib versus fludarabine, cyclophosphamide and rituximab (FCR) in patients with CLL. A retrospective multicenter 'real-world' study

Author

Levi, Shai, Bronstein, Yotam, Goldschmidt, Neta, Morabito, Fortunato, Ziv-Baran, Tomer, Del Poeta, Giovanni, Bairey, Osnat, Del Principe, Maria Ilaria, Fineman, Riva, Mauro, Francesca Romana, Gutwein, Odit, Reda, Gianluigi, Ruchlemer, Rosa, Sportoletti, Paolo, Laurenti, Luca, Shvidel, Lev, Coscia, Marta, Tadmor, Tamar, Varettoni, Marzia, Aviv, Ariel, Murru, Roberta, Braester, Andrei, Chiarenza, Annalisa, Visentin, Andrea, Pietrasanta, Daniela, Loseto, Giacomo, Zucchetto, Antonella, Bomben, Riccardo, Olivieri, Jacopo, Neri, Antonio, Rossi, Davide, Gaidano, Gianluca, Trentin, Livio, Foà, Robin, Cuneo, Antonio, Perry, Chava, Gattei, Valter, Gentile, Massimo, and Herishanu, Yair

Subjects
Settore MED/15
Published
2023

4. P571: OUTPATIENT INITIATION OF VENETOCLAX-AZACITIDINE FOR SELECTED ACUTE MYELOID LEUKEMIA PATIENTS IS FEASIBLE AND SAFE: A REAL WORLD SINGLE CENTER ANALYSIS

Author

Gat, Roi, primary, Neeman, Miri, additional, Levi, Shai, additional, Levi, Mor, additional, Eilati, Nili, additional, Bronstein, Yotam, additional, Shragai, Tamir, additional, Neuman, Tsipora, additional, Segman, Yafit, additional, Vitkon, Roy, additional, Mittelman, Moshe, additional, Avivi, Irit, additional, and Moshe, Yakir, additional

Published
2023
Full Text
View/download PDF

5. P651: REAL-WORLD EFFECTIVENESS OF VENETOCLAX-BASED REGIMENS IN PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA IN ISRAEL: UPDATE FROM THE MULTICENTER PROSPECTIVE REVEAL STUDY

Author

Herishanu, Yair, primary, Goldschmidt, Neta, additional, Itchaki, Gilad, additional, Bronstein, Yotam, additional, Levi, Itai, additional, Aviv, Ariel, additional, Fineman, Riva, additional, Dally, Najib, additional, Tadmor, Tamar, additional, Ronson, Aaron, additional, Abadi, Uri, additional, Shvidel, Levi, additional, Stemer, Galia, additional, Kay, Sigi, additional, Glait Santar, Chen, additional, Barak, Moran, additional, Rivlin, Noa, additional, Kaminsky, Natalie, additional, Cohen, Raanan, additional, Ofek, Keren, additional, Berelovich, Jenia, additional, Grunspan, Moshe, additional, and Benjamini, Ohad, additional

Published
2023
Full Text
View/download PDF

8. Efficacy of front‐line ibrutinib versus fludarabine, cyclophosphamide, and rituximab in patients with chronic lymphocytic leukemia: A retrospective multicenter “ Real‐World ” study

Author

Levi, Shai, primary, Bronstein, Yotam, additional, Goldschmidt, Neta, additional, Morabito, Fortunato, additional, Ziv‐Baran, Tomer, additional, Del Poeta, Giovanni, additional, Bairey, Osnat, additional, Del Principe, Maria Ilaria, additional, Fineman, Riva, additional, Mauro, Francesca Romana, additional, Gutwein, Odit, additional, Reda, Gianluigi, additional, Ruchlemer, Rosa, additional, Sportoletti, Paolo, additional, Laurenti, Luca, additional, Shvidel, Lev, additional, Coscia, Marta, additional, Tadmor, Tamar, additional, Varettoni, Marzia, additional, Aviv, Ariel, additional, Murru, Roberta, additional, Braester, Andrei, additional, Chiarenza, Annalisa, additional, Visentin, Andrea, additional, Pietrasanta, Daniela, additional, Loseto, Giacomo, additional, Zucchetto, Antonella, additional, Bomben, Riccardo, additional, Olivieri, Jacopo, additional, Neri, Antonio, additional, Rossi, Davide, additional, Gaidano, Gianluca, additional, Trentin, Livio, additional, Foà, Robin, additional, Cuneo, Antonio, additional, Perry, Chava, additional, Gattei, Valter, additional, Gentile, Massimo, additional, and Herishanu, Yair, additional

Published
2022
Full Text
View/download PDF

11. Improved outcomes in patients with chronic lymphocytic leukaemia infected during the omicron BA.5 subvariant surge.

Author

Bronstein, Yotam, Levi, Shai, and Herishanu, Yair

Subjects
*SARS-CoV-2 Omicron variant, *LYMPHOCYTIC leukemia, *CHRONIC leukemia, *COVID-19, *COVID-19 pandemic
Abstract

Summary: Patients with chronic lymphocytic leukaemia (CLL) infected with SARS‐CoV‐2 are at increased risk of severe COVID‐19 and death. The outcomes of CLL patients with COVID‐19 during the omicron subvariants and in particular with BA.5 are not fully elucidated. Here, we report the outcomes of 128 CLL patients diagnosed with COVID‐19 from December 2021 through November 2022. The hospitalization and 30‐day mortality rates were 26.6% (n = 34) and 4.7% (n = 6), respectively. Both hospitalizations and mortality were lower during the outbreaks of the BA.2 and BA.5 subvariants (17.2%, 0% vs. 15.2%, 0%, respectively) compared with the period dominated by the BA.1 subvariant (41.5%, 11.3%). [ABSTRACT FROM AUTHOR]

Published
2023
Full Text
View/download PDF

13. COVID-19 in patients with lymphoproliferative diseases during the Omicron variant surge

Author

Bronstein, Yotam, primary, Gat, Roi, additional, Levi, Shai, additional, Cohen, Yael C., additional, Luttwak, Efrat, additional, Benyamini, Noam, additional, Shragai, Tamir, additional, Vitkon, Roy, additional, Neaman, Miriam, additional, Eilaty, Nili, additional, Levi, Mor, additional, Trestman, Svetlana, additional, Perry, Chava, additional, Herishanu, Yair, additional, and Avivi, Irit, additional

Published
2022
Full Text
View/download PDF

14. Efficacy of front‐line ibrutinib versus fludarabine, cyclophosphamide, and rituximab in patients with chronic lymphocytic leukemia: A retrospective multicenter "Real‐World" study.

Author

Levi, Shai, Bronstein, Yotam, Goldschmidt, Neta, Morabito, Fortunato, Ziv‐Baran, Tomer, Del Poeta, Giovanni, Bairey, Osnat, Del Principe, Maria Ilaria, Fineman, Riva, Mauro, Francesca Romana, Gutwein, Odit, Reda, Gianluigi, Ruchlemer, Rosa, Sportoletti, Paolo, Laurenti, Luca, Shvidel, Lev, Coscia, Marta, Tadmor, Tamar, Varettoni, Marzia, and Aviv, Ariel

Published
2023
Full Text
View/download PDF

17. Association of a Third Dose of BNT162b2 Vaccine With Incidence of SARS-CoV-2 Infection Among Health Care Workers in Israel

Author

Spitzer, Avishay, primary, Angel, Yoel, additional, Marudi, Or, additional, Zeltser, David, additional, Saiag, Esther, additional, Goldshmidt, Hanoch, additional, Goldiner, Ilana, additional, Stark, Moshe, additional, Halutz, Ora, additional, Gamzu, Ronni, additional, Slobodkin, Marina, additional, Amrami, Nadav, additional, Feigin, Eugene, additional, Elbaz, Meital, additional, Furman, Moran, additional, Bronstein, Yotam, additional, Chikly, Amanda, additional, Eshkol, Anna, additional, Furer, Victoria, additional, Mayer, Talia, additional, Meijer, Suzy, additional, Melloul, Ariel, additional, Mizrahi, Michal, additional, Yakubovsky, Michal, additional, Rosenberg, Dana, additional, Safir, Ari, additional, Spitzer, Liron, additional, Taleb, Eyal, additional, Elkayam, Ori, additional, Silberman, Adi, additional, Eviatar, Tali, additional, Elalouf, Ofir, additional, Levinson, Tal, additional, Pozyuchenko, Katia, additional, Itzhaki-Alfia, Ayelet, additional, Sprecher, Eli, additional, Ben-Ami, Ronen, additional, and Henig, Oryan, additional

Published
2022
Full Text
View/download PDF

19. Efficacy of Front-Line Ibrutinib Versus Fludarabine, Cyclophosphamide and Rituximab (FCR) in Patients with CLL. a Multicenter "Real-World" Study

Author

Herishanu, Yair, primary, Levi, Shai, additional, Goldschmidt, Neta, additional, Morabito, Fortunato, additional, Bairey, Osnat, additional, Del Poeta, Giovanni, additional, Ziv Baran, Tomer, additional, Fineman, Riva, additional, Mauro, Francesca Romana, additional, Gutwein, Odit, additional, Reda, Gianluigi, additional, Ruchlemer, Rosa, additional, Sportoletti, Paolo, additional, Laurenti, Luca, additional, Shvidel, Lev, additional, Coscia, Marta, additional, Tadmor, Tamar, additional, Varettoni, Marzia, additional, Aviv, Ariel, additional, Murru, Roberta, additional, Breaster, Andrei, additional, Bronstein, Yotam, additional, Chiarenza, Annalisa, additional, Visentin, Andrea, additional, Pietrasanta, Daniela, additional, Loseto, Giacomo, additional, Zucchetto, Antonella, additional, Bomben, Riccardo, additional, Olivieri, Jacopo, additional, Neri, Antonino, additional, Rossi, Davide, additional, Gaidano, Gianluca, additional, Trentin, Livio, additional, Foa, Robin, additional, Cuneo, Antonio, additional, Gattei, Valter, additional, and Gentile, Massimo, additional

Published
2021
Full Text
View/download PDF

21. Spatial organization and early signaling of the B-cell receptor in CLL.

Author

Arbel, Yamit Shorer, Bronstein, Yotam, Dadosh, Tali, Kamdjou, Talia, Tsuriel, Shlomo, Shapiro, Mika, Katz, Ben-Zion, and Herishanu, Yair

Subjects
CHRONIC lymphocytic leukemia, IMMUNOGLOBULIN G, B cells
Abstract

Most chronic lymphocytic leukemia (CLL) clones express B-cell receptors (BcR) of both IgM/IgD isotypes; however, 5%-10% of CLL cases express isotypeswitched immunoglobulin G (IgG). The early signaling and spatial patterning of the various BcRs at steady state and after activation are still fully unresolved. Herein, we show higher expression of the BcR signalosome elements and a more robust constitutive cell-intrinsic proximal BcR signaling in CLL with unmutated IGHV expressing IgM isotype (IgM U-CLL), compared with IGHVmutated CLL (M-CLL) expressing either IgM or IgG isotypes. IgM in U-CLL is frequently located in the membrane plane in polarized patches, occasionally in caps, and sometimes inside the cells. Among M-CLL, IgM is scattered laterally in the membrane plane in a similar pattern as seen in normal B cells, whereas IgG is dispersed around the cell membrane in smaller clusters than in IgM U-CLL. Upon BcR engagement, both IgG and IgM expressing M-CLL showed attenuated signaling and only slight spatial reorganization dynamics of BcR microclusters and internalization, compared with the extensive reorganization and internalization of the BcR in IgM expressing U-CLL. The global gene signature of IgG M-CLL was closely related to that of IgM M-CLL rather than IgM U-CLL. Overall, we report fundamental differences in the basal composition, biochemical status, and spatial organization of the BcR in the three examined immunogenetic CLL subtypes that correlate with their clinical behavior. On the basis of our findings, IgG class-switched M-CLL likely represents the same disease as IgM M-CLL rather than a different biological and/or clinical entity. [ABSTRACT FROM AUTHOR]

Published
2022
Full Text
View/download PDF

23. Proteolysis Targeting Chimeras for BTK Efficiently Inhibit B-Cell Receptor Signaling and Can Overcome Ibrutinib Resistance in CLL Cells

Author

Shorer Arbel, Yamit, primary, Katz, Ben-Zion, additional, Gabizon, Ronen, additional, Shraga, Amit, additional, Bronstein, Yotam, additional, Kamdjou, Talia, additional, Globerson Levin, Anat, additional, Perry, Chava, additional, Avivi, Irit, additional, London, Nir, additional, and Herishanu, Yair, additional

Published
2021
Full Text
View/download PDF

26. Evolution of spike mutations following antibody treatment in two immunocompromised patients with persistent COVID‐19 infection.

Author

Bronstein, Yotam, Adler, Amos, Katash, Haytham, Halutz, Ora, Herishanu, Yair, and Levytskyi, Katia

Subjects
COVID-19, IMMUNOCOMPROMISED patients, CONVALESCENT plasma
Abstract

Immunocompromised patients have an increased risk of persistent COVID‐19 disease. We report here the clinical course of two patients with hematologic malignancies hospitalized due to severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2) infection. In both patients, viral evolution including new spike gene mutations that occurred following treatment with anti‐SARS‐CoV‐2 antibodies preparations, including convalescent plasma and bamlanivimab. These cases demonstrate the possibility of antibody‐resistant SARS‐CoV‐2 infections evolution in immunocompromised patients. Highlights: Patients with hematologic malignancies are at risk of persistent SARS‐CoV‐2 infection.Using anti‐SRAS‐CoV‐2 antibody preparations in immunocompromised patients may lead to the evolution of antibody‐resistant SRAS‐CoV‐2 infections.Antibody‐resistant SRAS‐CoV‐2 infections might have severe epidemiological implications. [ABSTRACT FROM AUTHOR]

Published
2022
Full Text
View/download PDF

28. Six-month antibody persistence after BNT162b2 mRNA COVID-19 vaccination in patients with chronic lymphocytic leukemia

Author

Chava Perry, Irit Avivi, Tomer Ziv-Baran, Gabi Shefer, Yair Herishanu, Yotam Bronstein, Lydia Scarfò, Shai Levi, Miguel Morales Moshiashvili, Paolo Ghia, Herishanu, Yair, Avivi, Irit, Levi, Shai, Shefer, Gabi, Bronstein, Yotam, Morales Moshiashvili, Miguel, Ziv-Baran, Tomer, Scarfò, Lydia, Perry, Chava, and Ghia, Paolo

Subjects
2019-20 coronavirus outbreak, COVID-19 Vaccines, Coronavirus disease 2019 (COVID-19), COVID-19 Vaccine, Chronic lymphocytic leukemia, Antibodies, Viral, Persistence (computer science), Research Letter, medicine, Humans, In patient, RNA, Messenger, BNT162 Vaccine, Messenger RNA, biology, SARS-CoV-2, business.industry, Vaccination, COVID-19, antibody response, persistence, Hematology, medicine.disease, Leukemia, Lymphocytic, Chronic, B-Cell, Immunology, biology.protein, BNT162b2, Antibody, business, CLL
Published
2022

Catalog

Books, media, physical & digital resources
See catalog results